cystic fibrosis

Kalydeco Open to Infants in Europe Starting at 4 Months Old

The European Commission has approved Kalydeco (ivacaftor), by Vertex Pharmaceuticals, to treat infants as young as four months old with cystic fibrosis (CF) caused by certain mutations. The decision to extend Kalydeco’s label to younger babies, weighing at least 5 kg (about 11 lbs) and with relevant mutations, follows…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.